Related Experiment Video
Updated: Jan 7, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
636
Nano-Enhanced Diets: Advancing Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) - A Review
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, 45363, Indonesia.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|December 29, 2025
Summary
Nano-based nutrient delivery systems show promise for treating Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) by improving nutraceuticals' bioavailability. Further research into nanotoxicity and scalability is needed for clinical translation.
Area of Science:
- Hepatology
- Nanotechnology
- Pharmacology
Background:
- Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) presents a significant global health burden.
- Nutraceuticals show potential for liver protection but face challenges with solubility and oral bioavailability.
Purpose of the Study:
- To evaluate the translational potential of nano-based nutrient delivery systems for MASLD.
- To analyze how nanoplatforms enhance pharmacokinetic parameters and therapeutic efficacy.
Main Methods:
- Review of in vivo evidence on nanoemulsions, liposomes, and polymeric nanoparticles.
- Analysis of pharmacokinetic modifications and therapeutic outcomes in preclinical models.
Main Results:
- Nanoplatforms significantly improve solubility and stability of nutraceuticals.
- Preclinical studies show reduced steatosis and fibrosis with nanocarriers compared to conventional compounds.
- Challenges include lack of long-term nanotoxicity data and scalability issues.
Conclusions:
- Nano-based delivery systems offer a promising strategy to overcome formulation limitations for nutraceuticals in MASLD treatment.
- Future directions involve green nanotechnology with GRAS biopolymers for sustainable and safe clinical translation.
